Partial
Partially Aligned
Patient Risk:
Low
Summary
Overall alignment is partial: the mechanism claim is supported by the label description, but the indication claim is overbroad relative to the label’s specific approved indication (polyneuropathy of hATTR amyloidosis in adults). Claims about HCPCS/billing codes are not supported by the provided FDA label sections. The evaluation also does not assess several materially important label safety/administration sections.
Category Scores
Accurate Statements
ONPATTRO contains patisiran described as a double-stranded small interfering RNA (siRNA) (supports RNA interference mechanism concept).
11 DESCRIPTION: 'ONPATTRO contains patisiran, a double-stranded small interfering ribonucleic acid (siRNA)'.
HCPCS code claims are absent from the provided label sections and thus are not verifiable from the supplied FDA label content.
Unsupported Statements
Onpattro (patisiran) is an RNA interference therapy.
The label provided uses 'siRNA' description but does not use the exact phrase 'RNA interference therapy.'
Onpattro (patisiran) is indicated for hereditary transthyretin (hATTR) amyloidosis.
Label indication is specifically for the 'polyneuropathy' of hereditary transthyretin-mediated amyloidosis in adults, not hATTR amyloidosis broadly.
The HCPCS codes used for Onpattro are tied to how the drug is billed (including billing unit and formulation/strength).
No HCPCS/billing-code information is present in the provided label sections.
The HCPCS codes used for Onpattro can vary by payer and setting.
No information about payer- or setting-dependent HCPCS variation is present in the provided label sections.
Contradictions
Important Omissions
Several important label elements were not evaluated against the claims set, including contraindications, boxed warnings, warnings/precautions, drug interactions, and administration/dosing precautions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are mainly about mechanism and indication scope; the main potential label-accuracy issue is overbreadth of the indication. The evaluation does not include safety/contraindication verification, but no unsafe dosing/safety instructions were claimed in the provided extracted claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Indication claim is overbroad versus the label’s specific indication (polyneuropathy of hATTR amyloidosis in adults). HCPCS/billing-code claims are not supported by the provided label sections.
Suggested Improvement
Restrict the indication language to 'polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults' and remove/avoid any HCPCS/billing-code claims unless supported by the full FDA label or explicitly provided label sections.